- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02909556
ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single arm, prospecitve, multicenter, non-randomized and open trial. The purpose of this trial is to collect and safety and performance data concerning the ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System
The ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System are intended for use in minimally invasive, transcatheter aortic valve replacement (TAVR) using transfemoral access in patients presenting with severe aortic valve stenosis.
The primary objective is to evaluate the safety and performance of the study device in patients presenting with severe aortic stenosis (AS) considered to be high risk for surgery.
The secondary objective is to evaluate adverse events and study device performance.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
-
-
-
Bad Nauheim, Germany, 61231
- Kerckhoff-Klinik Forschungsgesellschaft mbH
-
Dortmund, Germany
- Johannes Hospital
-
Halle (Saale), Germany, 06120
- Universitätsklinikum Halle - Universitätsklinik und Poliklinik für Herzchirurgie
-
Hamburg, Germany, 20246
- Universitäres Herzzentrum Hamburg - Klinik und Poliklinik für Herz- und Gefäßchirurgie
-
Leipzig, Germany, 04289
- Herzzentrum Leipzig GmbH
-
München, Germany, 80636
- Deutsches Herzzentrum München
-
Regensburg, Germany, 93053
- Universitätsklinik Regensburg
-
-
-
-
-
Luzern, Switzerland, 6000
- Luzerner Kantonsspital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient 75 years of age and older
Severe aortic stenosis defined as:
- Mean aortic gradient > 40 mmHg or
- Peak jet velocity > 4.0 m/s or
- Aortic valve area of < 1.0 cm2
High risk candidate for conventional AVR defined as:
- Logistic EuroSCORE 1 ≥ 20% or
- STS Score ≥ 8% or
- Heart team (cardiologist and cardiac surgeon) consensus that patient is not a surgical candidate for conventional AVR due to significant co-morbid conditions unrelated to aortic stenosis
- NYHA Functional Class > II
- Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT
- Patient willing to participate in the study and provides signed informed consent
Exclusion Criteria:
- Congenital aortic stenosis or unicuspid or bicuspid aortic valve
- Non-stenotic Aortic Insufficiency
- Severe eccentricity of calcification
- Severe mitral regurgitation (>2+)
- Presence of mitral bioprosthesis
- Presence of previously implanted aortic bioprosthesis
- Presence of prosthetic ring
- Anatomy NOT appropriate for transfemoral implant due to the size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries
- Thoracic (TAA) or abdominal (AAA) aortic aneurysm
- Presence of endovascular stent graft for treatment of TAA or AAA
- Trans-oesophageal echocardiogram (TEE) is contraindicated
- Evidence of intra-cardiac mass, thrombus or vegetation
- Severe ventricular dysfunction with ejection fraction < 20%
- Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
- Acute Myocardial Infarction within 1 month prior to implant procedure
- Previous TIA or stroke within 3 months prior to implant procedure
- Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant procedure
- Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
- Severe coagulation conditions
- Refusal of blood transfusions
- Systolic pressure <80mmHg, cardiogenic shock, need for inotropic support or IABP
- Hypertrophic cardiomyopathy with or without obstruction
- Active bacterial endocarditis or other active infections
- Hepatic failure (> Child B)
- Chronic renal dysfunction with serum creatinine > 2.5 mg/dL or renal dialysis
- Refusal of surgery
- Severe COPD requiring home oxygen
- Neurological disease severely affecting ambulation or daily functioning, or dementia
- Life expectancy < 12 months due to non-cardiac co-morbid conditions
- Inability to tolerate anticoagulation therapy
- Contraindication to contrast media or allergy to nickel
- Currently participating in an investigational drug or another device study
- Non-valvular aortic stenosis
- Non-calcific acquired aortic stenosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACURATE neo AS
|
Transcatheter aortic valve replacement via transfemoral access
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of all-cause mortality at 30 days follow-up
Time Frame: 30 days post-implant
|
30 days post-implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of clinical events as defined per VARC guidelines
Time Frame: 7 days, 30 days, 12 months post-implant
|
Clinical events:
|
7 days, 30 days, 12 months post-implant
|
Procedural success
Time Frame: Day of implant
|
2. Procedural success defined as absence of complications arising during implantation of the prosthetic valve such as: inability to properly seat the valve in the annulus; need for more than one aortic bioprosthesis (valve in valve); or if a surgical aortic valve replacement is required to correct a severe aortic regurgitation or procedure complication
|
Day of implant
|
Device success
Time Frame: Day of implant
|
3. Device success defined as:
|
Day of implant
|
VARC Composite Safety at 30 days
Time Frame: 30 days
|
30 days
|
|
Clinical improvement from baseline as per NYHA Functional Classification
Time Frame: 7 days, 30 days, 12 months post-implant
|
7 days, 30 days, 12 months post-implant
|
|
Improvement from baseline in hemodynamic function: effective orifice area, mean transprosthetic gradient
Time Frame: 7 days, 30 days, 12 months
|
7 days, 30 days, 12 months
|
|
Total aortic regurgitation
Time Frame: 7 days, 30 days, 12 months
|
7 days, 30 days, 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Helge Möllmann, Prof., Klinik für Innere Medizin - St.-Johannes-Hospital - Dortmund, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on Transcatheter aortic valve replacement
-
IRCCS Policlinico S. DonatoRecruiting
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Ole De BackerBoston Scientific Corporation; Abbott; Edwards Lifesciences; Symetis SAActive, not recruitingHeart Diseases | Cardiovascular Diseases | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow ObstructionFinland, Norway, Sweden, Denmark, Iceland
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
University of PadovaFondazione GISE OnlusRecruiting
-
OptimapharmEdwards LifesciencesActive, not recruitingAortic Valve Stenosis | Heart Valve DiseasesUnited Kingdom, Italy, Germany, France, Austria, Switzerland, Finland, Czechia, Belgium, Netherlands, Cyprus, Ireland
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina
-
Medical University of WarsawRecruitingAortic Valve Stenosis | Ventricular Outflow Obstruction, LeftPoland